<DOC>
	<DOCNO>NCT00004022</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop cancer cell grow . Combining different type biological therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness biological therapy follow surgery treat patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Biological Therapy Following Surgery Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate efficacy immunotherapy irradiate autologous tumor cell vaccine sargramostim ( GM-CSF ) follow monoclonal antibody OKT3- activate T lymphocytes interleukin-2 combination surgery term response rate patient stage III IV malignant melanoma . - Determine immunogenicity malignant melanoma patient population . OUTLINE : Patients stratify accord extent disease , extent antigen specific response vaccination , performance status ( 0 vs 1 ) , prior therapy ( yes v ) , gender . Patients undergo surgical resection tumor week 1 . Within 1-2 week surgery , patient vaccinate irradiated autologous tumor cell sargramostim ( GM-CSF ) , receive GM-CSF alone intradermally vaccination site daily 4 day . Patients revaccinated 2 week later . Patients undergo peripheral blood mononuclear cell collection two week second vaccination . Peripheral blood mononuclear cell stimulate anti-CD3 monoclonal antibody ( OKT3 ) interleukin-2 , produce activate T lymphocytes . The activated T lymphocyte infuse IV 1-6 hour follow 5 dos interleukin-2 IV every day 10 day . Treatment continue absence disease progression unacceptable toxicity . Patients may receive one additional course immunotherapy . Patients follow every 3 month 2 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Muromonab-CD3</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage III IV malignant melanoma Resectable disease At least 50,000,000 viable cell obtain surgical specimen use immunization part study PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 0 1 Life expectancy : At least 6 month Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least low limit normal No active recent uncontrolled bleeding Hepatic : Bilirubin normal SGOT great 2 time upper limit normal ( ULN ) ( great 5 time ULN liver metastasis present ) Renal : Creatinine normal Other : Negative stool guaiac No impaired immunity No uncontrolled diabetes No active uncontrolled infection No serious disease No malignancy within past 5 year except curatively treat basal squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics Other : At least 2 week since prior therapy recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>